DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2005/0112199 A1 Padval Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2005/0112199 A1 Padval Et Al US 2005O112199A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0112199 A1 Padval et al. (43) Pub. Date: May 26, 2005 (54) THERAPEUTIC REGIMENS FOR Said application No. 10/947,455 is a continuation-in ADMINISTERING DRUG COMBINATIONS part of application No. 10/944,574, filed on Sep. 17, 2004, and which is a continuation-in-part of applica (76) Inventors: Mahesh Padval, Waltham, MA (US); tion No. 10/777,518, filed on Feb. 12, 2004. Peter Elliott, Marlboro, MA (US) (60) Provisional application No. 60/520,446, filed on Nov. Correspondence Address: 13, 2003. Provisional application No. 60/512,415, CLARK & ELBING LLP filed on Oct. 15, 2003. Provisional application No. 101 FEDERAL STREET 60/557,496, filed on Mar. 30, 2004. BOSTON, MA 02110 (US) Publication Classification (21) Appl. No.: 10/947,769 (51) Int. Cl. .................................................. A61K 9/22 (22) Filed: Sep. 23, 2004 (52) U.S. Cl. .............................................................. 424/468 Related U.S. Application Data (57) ABSTRACT (63) Continuation-in-part of application No. 10/947,455, filed on Sep. 20, 2004, which is a continuation of The invention features dosing regimens for the administra application No. 10/777,517, filed on Feb. 12, 2004, tion of combination therapies, wherein one of the drugs of which is a continuation-in-part of application No. the combination is formulated for Sustained release, or 10/670,488, filed on Sep. 24, 2003. administered repeatedly, and compositions related thereto. Patent Application Publication May 26, 2005 Sheet 1 of 2 US 2005/0112199 A1 FIG. 1 1000 -O-Amoxapine -O-Prednisolone O 2 4 6 8 1 0 12 14 16 18 20 22 24 26 Time after administration (h) Patent Application Publication May 26, 2005 Sheet 2 of 2 US 2005/0112199 A1 FIG. 2 150 -O-Paroxetine -O-Prednisolone 125 S S. 5 100 of s 75 - C 50 O St 25 O 7. O O €1. OO-O-O O 2 4 6 8 10 12 14 16 18 20 22 24 26 Time after administration (h) US 2005/0112199 A1 May 26, 2005 THERAPEUTIC REGIMENS FOR 0008. The invention further features a pharmaceutical ADMINISTERING DRUG COMBINATIONS composition including a unit dosage form including a first drug selected from tricyclic compounds, SSRIs, SNRIs, CROSS-REFERENCE TO RELATED NSIDIs, antihistamines, and tetra-Substituted pyrimidopyri APPLICATIONS midines, and a Second drug formulated for Sustained release. 0001. This application is Continuation-in-part of U.S. 0009. The invention features a kit including: (a) a first Utility application entitled “Methods and Reagents for the drug not formulated for Sustained release, (b) a said Second Treatment of Diseases and Disorders Associated with drug formulated for Sustained release, and (c) instructions Increased Levels of Proinflammatory Cytokines, filed Sep. for administering Simultaneously, or within 30 minutes of 22, 2004, which is a Continuation of U.S. Utility application one another, Said first drug and Said Second drug. Ser. No. 10/777,517, filed Feb. 12, 2004, which is a Con 0010. In the above methods, compositions, and kits, the tinuation-in-part of U.S. Utility application Ser. No. 10/670, first drug or Second drug is desirably a tricyclic compound, 488, filed Sep. 24, 2003, and claims benefit of U.S. Provi SSRI, SNRI, NSIDI, antihistamine, corticosteroid, or a tetra sional Application No. 60/557,496, filed Mar. 30, 2004, each Substituted pyrimidopyrimidine. of which is incorporated herein by reference. 0011. In any of the above methods, compositions, and BACKGROUND OF THE INVENTION kits, the first drug and the Second drug are optionally formulated together in a unit dosage form. Unit dosage 0002 The invention relates to dosing regimens for the forms include, for example, a bilayer tablet having a first administration of combination therapies. layer including the first drug not formulated for Sustained release and a Second layer including the Second drug for 0.003 Combination therapy refers to the administration of mulated for Sustained release. The unit dosage form may two or more drugs for the treatment of a disease or disorder, also be a tablet having an inner core including the Second or two or more comorbid conditions. While in Some cases drug formulated for Sustained release and an outer coat each component of the combination is acting independently including the first drug not formulated for Sustained release. of the other(s), in other cases the two drugs may be acting Furthermore, the unit dosage form may be a capsule having in a combinatorial manner, e.g., a Synergistically, to produce beads including the Second drug formulated for Sustained a result that would not be achieved by the administration of release and beads including the first drug not formulated for the two drugs in a non-overlapping manner. Sustained release 0004) Notwithstanding the foregoing, it may be that combination therapy falling in the latter category may 0012 Any of the unit dosage forms described herein may include drugs having different pharmacokinetic properties further include the Second drug not formulated for Sustained (e.g., different Ta times). In these cases, the full benefit of release. the combination therapy is not being realized. 0013 In any of the above methods, compositions, and kits, the first drug may be a tricyclic compound and the 0005 Thus, there is a desire to develop better methods for Second drug may be a corticosteroid, Such as the combina combination therapy. tion of amoxapine and prednisolone or the combination of nortriptyline and budesonide; the first drug may be an SSRI SUMMARY OF THE INVENTION and the Second drug may be a corticosteroid, Such as the 0006. In a first aspect, the invention features a method of combination of paroxetine and prednisolone; the first drug enhancing the efficacy of a drug combination. The method may be dipyridamole and the Second drug may be a corti includes the steps of i) administering a first drug in an costeroid, Such as prednisolone; the fist drug may be an amount Sufficient to produce an effective plasma concentra NSIDI and the Second drug may be an antihistamine, Such as tion of the first drug for a period of time T, and ii) the combination of cycloSporin A and loratadine, or the first administering a Second drug in a manner Sufficient to pro drug may be dipyridamole and the Second drug may be an duce an effective plasma concentration of the Second drug antihistamine, Such as loratadine. for at least 70% of time T. Desirably, the second drug is 0014. The compositions can be formulated for any route administered in a manner Sufficient to produce an effective of administration. For example, the combination of nortrip plasma concentration of the Second drug for at least 75%, tyline and budesonide can be formulated for inhalation. 80%, 85%, or even 90% of time T. Optionally, some or all Desirably, the combination is formulated for oral adminis of the Second drug is formulated for Sustained release, and/or tration. the Second drug is administered more than once during time T. 0015 Compounds useful in the invention include those described herein in any of their pharmaceutically acceptable 0007. The invention also features a method of adminis tering a drug combination. This method includes the Steps of forms, including isomerS Such as diastereomers and enanti administering Simultaneously, or within 30 minutes of one omers, Salts, esters, Solvates, and polymorphs thereof, as another, a first drug not formulated for Sustained release and well as racemic mixtures and pure isomers of the com a second drug formulated for Sustained release, wherein a) pounds described herein. the first drug produces a peak plasma concentration at Ta, 0016. The methods, compositions, and kits described b) the Second drug produces a peak plasma concentration at herein can also be used to generate information useful, for Ta2, and c) Ta2 is equal to or greater than Tinas, example, for increasing investment in a company or increas provided that if the second drug were not formulated for ing consumer demand for the methods, compositions, and/or Sustained release Tmax1 Tmax2: kits. US 2005/0112199 A1 May 26, 2005 0.017. The invention therefore features a method of mental approval includes, for example, the approval of a increasing consumer demand for a pharmaceutical compo drug application by the Food and Drug Administration, Sition, therapeutic regimen, or kit described herein. The among others. method includes the Step of disseminating information about 0024. By “SSRI” is meant any member of the class of the pharmaceutical composition, therapeutic regimen, or kit. compounds that (i) inhibit the uptake of Serotonin by neu 0.018. The invention further features a method of increas rons of the central nervous System, (ii) have an inhibition ing investment in a company Seeking governmental approval constant (Ki) of 10 nM or less, and (iii) a selectivity for for the Sale of a pharmaceutical composition, therapeutic Serotonin over norepinephrine (i.e., the ratio of Ki(norepi regimen, or kit described herein. The method includes the nephrine) over Ki(serotonin)) of greater than 100. Typically, Steps of i) disseminating information about the pharmaceu SSRIs are administered in dosages of greater than 10 mg per tical composition, therapeutic regimen, or kit, and ii) dis day when used as antidepressants. Exemplary SSRIs for use Seminating information about the intent of the company to in the invention are described herein. market the pharmaceutical composition, therapeutic regi 0025 By “corticosteroid” is meant any naturally occur men, or kit. ring or Synthetic compound characterized by a hydrogenated 0.019 Consumer demand for a pharmaceutical composi cyclopentanoperhydrophenanthrene ring System and having tion or kit described herein, optionally with instructions to immunosuppressive and/or antinflammatory activity.
Load more

Recommended publications
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma Et Al
    US 20100081713A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma et al. (43) Pub. Date: Apr. 1, 2010 (54) COMPOSITIONS AND METHODS FOR (22) Filed: Mar. 18, 2009 TREATINGVIRAL INFECTIONS Related U.S. Application Data (75) Inventors: Geeta Sharma, Singapore (SG); (60) Provisional application No. 61/069,917, filed on Mar. Ralf Altmeyer, Singapore (SG); 19, 2008. Vishal Pendharker, Singapore (SG); Yu Chen, Singapore (SG); Publication Classification Michael Foley, Chestnut Hill, MA (51) Int. Cl. (US) A63L/35 (2006.01) A6II 3L/25 (2006.01) Correspondence Address: A63L/35 (2006.01) Gearhart Law LLC A6II 3/13 (2006.01) 4 Femdale Avenue A6IP3L/2 (2006.01) Chatham, NJ 07928 (US) (52) U.S. Cl. .......... 514/459; 514/529; 514/647: 514/662 (73) Assignee: CombinatoRx, (Singapore) Pte. (57) ABSTRACT Ltd. The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infec (21) Appl. No.: 12/406,716 tion caused by an influenza virus). Patent Application Publication Apr. 1, 2010 Sheet 1 of 2 US 2010/0081713 A1 ------ 80 r -0. Vehicle 0.5% HPMC g - - Sertraline-30mg/kg/day - £ 60 “A Sertraline-100mg/kg/day/kg/day i -v. Oseltamivir-30mg/kg/day ...i -0. Oseltamivir-100mg/kg/day -0. (Sertraline 30mg/kg+ . 40 Prednisolone 0.1 mg/Kg) Figure 1 Patent Application Publication Apr. 1, 2010 Sheet 2 of 2 US 2010/0081713 A1 100 468OOO 2 O Wehicle Sentraline 10 mg/kg Sentraline 30mg/kg Setraline 100mg/kg Figure 2 US 2010/008 1713 A1 Apr.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • W O 2010/004256 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization IN International Bureau (10) International Publication Number (43) International Publication Date 14 January 2010 (14.01.2010) PCT W O 2010/004256 Al (51) International Patent Classification: Block B, Holland Park, Holland Drive, Newcastle Upon A61K 31/05 (2006.01) A61K31/29 (2006.01) Tyne Tyne & Wear NE2 4LZ (GB). A61K 31/055 (2006.01 ) A61K 31/343 (2006.01 ) A61K 31/06 (2006.01) A61K 31/415 (2006.01) (74) Agent: GILHOLM, Stephen, Philip; Pheons Intellec A61K31/135 (2006.01) A61K 31/485 (2006.01) tual Property, Buzzard Office, The Hawk Creative Busi A 61K 31/1357(2006.0l1) A 61K 31/45 (2006.0 1) ness Park, Easingwold, A61K31/137 (2006.01 ) A61K 31/5415 (2006.01 ) York YO61 3FF (GB). A61K31/167(2006.01) A61K 31/616 (2006.01) (81) Designated States (unless otherwise indicated, for every A61K 31/194 (2006.01) A61P 25/24 (2006.01) kind of nationalprotection available>: AE, AG, AL, AM, (21) International Application Number:AT, AU, AZ, BA, BB, BG, , BR, BW, BY, BZ, CN, CO, CR, CU, CZ, DF, DK, DM, DO, PCT/GB2009/001515PCT/B209/00515 DZ,CA, CH,FC, FE,CL, EG, ES, Fl, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, 11, IL, IN, IS, JP, KE, KG, KM, KN, KP, 17 June 2009 (17.06.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MN, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • WO 2007/061529 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 31 May 2007 (31.05.2007) PCT WO 2007/061529 Al (51) International Patent Classification: GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, A61K 9/14 (2006.01) KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV,LY,MA, MD, MG, MK, MN, MW, MX, MY, MZ, (21) International Application Number: NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, PCT/US2006/040197 SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (22) International Filing Date: 13 October 2006 (13.10.2006) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (26) Publication Language: English ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV,MC, NL, PL, PT, (30) Priority Data: RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, 11/282,507 18 November 2005 (18.1 1.2005) US GN, GQ, GW, ML, MR, NE, SN, TD, TG). (71) Applicant (for all designated States except US): SCI- Declarations under Rule 4.17: DOSE PHARMA INC.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0064805 A1 Obae Et Al
    US 2011 OO64805A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0064805 A1 Obae et al. (43) Pub. Date: Mar. 17, 2011 (54) POROUS CELLULOSE AGGREGATE AND Publication Classification MOLDING COMPOSITION THEREOF (51) Int. Cl. (75) Inventors: Kazuhiro Obae, Tokyo (JP); A69/20 (2006.01) HidekiO O Amakawa, Tokyo (JP); A6IR 9/16 (2006.01) Ichirochiro Ibuki,Ibuki.T Tokyo (JP)JP A6II 3/663/167 (2006.01) (73) Assignee: ASAHIKASE CHEMICALS A63L/92A6II 3/34 308:2006.O1 CORPORATION, Tokyo (JP) CI3K L/02 (2006.01) 21) Appl. No.: 12A926,318 (52) U.S. Cl. ......... 424/464; 424/499; 514/630; 514/622: (21) Appl. No 9 514/474; 514/570; 127/34; 127/37 (22) Filed: Nov. 9, 2010 (57) ABSTRACT Related U.S. Application Data A porous cellulose aggregate characterized by having a sec - - - ondary aggregate structure resulting from aggregation of pri (62) Division of application No. 11/918,979, filed on Oct. mary cellulose particles, having a pore Volume within a par 22, 2007, filed as application No. PCT/JP2006/308414 ticle of 0.265 to 2.625 cm/g, containing I-type crystals and on Apr. 21, 2006. having an average particle size of over 30 to 250 Lim, a specific surface area of 0.1 to less than 20 m/g, a repose angle of 25° (30) Foreign Application Priority Data to less than 44° and a swelling degree of 5% or more, and characterized by having the property of disintegrating in Apr. 22, 2005 (JP) ................................. 2005-124477 Water. Patent Application Publication Mar.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0201597 A1 CHASE Et Al
    US 20110201597A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0201597 A1 CHASE et al. (43) Pub. Date: Aug. 18, 2011 (54) METHOD AND COMPOSITION FOR Publication Classification TREATING ALZHEIMER-TYPE DEMENTA (51) Int. Cl. (76) Inventors: Thomas N. CHASE, Washington, A6II 3/55 (2006.01) DC (US); Kathleen E. A6II 3/445 (2006.01) CLARENCE-SMITH, A6IP 25/28 (2006.01) Washington, DC (US) (52) U.S. Cl. ......................................... 514/215: 514/319 (21) Appl. No.: 13/051,181 (57) ABSTRACT (22) Filed: Mar. 18, 2011 There is described a method for increasing the maximal tol erated dose and thus the efficacy of an acetylcholinesterase Related U.S. Application Data inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by (63) Continuation-in-part of application No. 12/880,395, administration of said AChEI in combination with a non filed on Sep. 13, 2010, Continuation-in-part of appli anticholinergic antiemetic agent, whereby an enhanced ace cation No. PCT/US2010/002475, filed on Sep. 13, tylcholinesterase inhibition in the CNS of said patient is 2010, Continuation-in-part of application No. 12/934, achieved and alleviation of the symptoms of Alzheimer type 140, filed on Sep. 23, 2010, filed as application No. dementia in said patient is thereby improved to a greater PCT/US09/01662 on Mar. 17, 2009. extent. The use of a non-anticholinergic antiemetic agent for (60) Provisional application No. 61/272.382, filed on Sep. the preparation of a pharmaceutical composition for the treat 18, 2009, provisional application No.
    [Show full text]
  • Wo 2008/033466 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 20 March 2008 (20.03.2008) WO 2008/033466 A2 (51) International Patent Classification: [US/US]; 1750 Washington Street, Boston, MA 021 18 A61K 31/4704 (2006.01) (US). ALTMEYER, RaIf [DE/SG]; 19 Cairnhill Circle, Apartment 17-06, Singapore 229768 (SG). (21) International Application Number: PCT/US2007/019932 (74) Agent: BELLIVEAU, Michael, J.; Clark & Elbing LLP, 101 Federal Street, Boston, MA 021 10 (US). (22) International Filing Date: 13 September 2007 (13.09.2007) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Filing Language: English AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, (26) Publication Language: English ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (30) Priority Data: LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, 60/844,463 14 September 2006 (14.09.2006) US MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, 60/874,061 11 December 2006 (11.12.2006) US PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (71) Applicant (for all designated States except US): COM- ZM, ZW BINATORX (SINGAPORE) PRE.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0113483 A1 SINGH (43) Pub
    US 20100113483A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0113483 A1 SINGH (43) Pub. Date: May 6, 2010 (54) COMPOSITIONS OF 5-HT3 ANTAGONISTS (60) Provisional application No. 60/817,666, filed on Jun. AND DOPAMINE D2 ANTAGONSTS FOR 29, 2006. TREATMENT OF DOPAMNE-ASSOCATED CHRONIC CONDITIONS Publication Classification (51) Int. Cl. (76) Inventor: NIKHILESH N. SINGH, Mill A 6LX 3/59 (2006.01) Valley, CA (US) A6IP 25/30 (2006.01) Correspondence Address: (52) U.S. Cl. ................................................... S14/259.41 O'Melveny & Myers LLP (57) ABSTRACT IP&T Calendar Department LA-13-A7 400 South Hope Street The present invention provides novel compositions compris Los Angeles, CA 90071-2899 (US) ing a combination of a 5-HT receptor antagonist and a selec tive dopamine D receptor antagonist for the treatment of (21) Appl. No.: 12/684,024 obsessive, impulsive and compulsive behavioral activities and other dopamine pathway-associated disorders or condi tions. Preferably, the pharmaceutical compositions of the (22) Filed: Jan. 7, 2010 present invention comprise amounts of the 5-HT receptor antagonist ondansetron and a selective dopamine D receptor Related U.S. Application Data antagonist, Such as risperidone or olanzapine, that are suffi (63) Continuation of application No. 1 1/780.442, filed on cient to control a Subject's obsessive, impulsive and compul Jul.19, 2007, now abandoned, which is a continuation sive behavioral activities. Kits comprising the combination of of application No. 1 1/824,201, filed on Jun. 28, 2007, antagonists for the treatment of addictive disorders such as now abandoned.
    [Show full text]